Carbamazepine Treatment for Cocaine Dependence - 5

This study has been completed.

Sponsor:

Collaborator:

National Institute on Drug Abuse (NIDA)

Information provided by (Responsible Party):

James Cornish, University of Pennsylvania

ClinicalTrials.gov Identifier:

NCT00000191

First received: September 20, 1999

Last updated: May 26, 2015

Last verified: May 2015

History of Changes

Purpose

The purpose of this study is to assess carbamazepine as a pharmacotherapy for cocaine dependence.

Condition	Intervention	Phase
Cocaine-Related Disorders	Drug: Carbamazepine	Phase 2


Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Carbamazepine Treatment for Cocaine Dependence

Resource links provided by NLM:

Drug Information available for: Cocaine hydrochloride Carbamazepine Carbamazepine dihydrate

U.S. FDA Resources

Further study details as provided by University of Pennsylvania:


Estimated Enrollment:	0
Study Start Date:	January 1991
Study Completion Date:	February 1994
Primary Completion Date:	February 1994 (Final data collection date for primary outcome measure)

Eligibility


Ages Eligible for Study:	21 Years to 51 Years (Adult)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000191

Locations


United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104 6178

Sponsors and Collaborators

University of Pennsylvania

National Institute on Drug Abuse (NIDA)

Investigators


Principal Investigator:	James Cornish, M.D.	University of Pennsylvania

More Information

Publications:

Cornish JW, Maany I, Fudala PJ, Neal S, Poole SA, Volpicelli P, O'Brien CP. Carbamazepine treatment for cocaine dependence. Drug Alcohol Depend. 1995 Jun;38(3):221-7.


Responsible Party:	James Cornish, Principal Investigator, University of Pennsylvania
ClinicalTrials.gov Identifier:	NCT00000191 History of Changes
Other Study ID Numbers:	NIDA-00144-5 3R01DA012268 K20-00144-5
Study First Received:	September 20, 1999
Last Updated:	May 26, 2015
Health Authority:	United States: Federal Government

Keywords provided by University of Pennsylvania:


Cocaine Dependence Carbamazepine

Additional relevant MeSH terms:


Cocaine-Related Disorders Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Cocaine Carbamazepine Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents Vasoconstrictor Agents Dopamine Uptake Inhibitors	Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter Agents Anticonvulsants Antimanic Agents Tranquilizing Agents Psychotropic Drugs Analgesics, Non-Narcotic Analgesics Cytochrome P-450 CYP3A Inducers Cytochrome P-450 Enzyme Inducers

ClinicalTrials.gov processed this record on September 28, 2016

To Top